Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Common Equity (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Common Equity data on record, last reported at -$88.9 million in Q3 2025.

  • For Q3 2025, Common Equity fell 3.84% year-over-year to -$88.9 million; the TTM value through Sep 2025 reached -$88.9 million, down 3.84%, while the annual FY2024 figure was -$93.1 million, 64.76% down from the prior year.
  • Common Equity reached -$88.9 million in Q3 2025 per BTAI's latest filing, up from -$107.7 million in the prior quarter.
  • Across five years, Common Equity topped out at $194.0 million in Q1 2022 and bottomed at -$107.7 million in Q2 2025.
  • Average Common Equity over 4 years is -$5.9 million, with a median of -$56.5 million recorded in 2023.
  • Peak YoY movement for Common Equity: tumbled 1367.07% in 2024, then fell 3.84% in 2025.
  • A 4-year view of Common Equity shows it stood at $76.8 million in 2022, then plummeted by 173.6% to -$56.5 million in 2023, then tumbled by 64.76% to -$93.1 million in 2024, then grew by 4.49% to -$88.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were -$88.9 million in Q3 2025, -$107.7 million in Q2 2025, and -$90.2 million in Q1 2025.